Sonnet BioTherapeutics Holdings Inc (SONN) News

Form 8-K - Current report

Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold’ tumors ‘hot’ Topline safety...

Form 8-K - Current report

Form 8-K - Current report

Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series

PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or...

Form 8-K - Current report

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer

Preclinical data has demonstrated the potential of SON-1210, the first albumin-binding bifunctional IL-12/IL-15...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Ongoing progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant...

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report